Interestingly, a recent phase II study using a CD95L-binding fusion protein in glioblastoma demonstrated that CD95 pathway inhibition in combination with radiotherapy represents an innovative concept with clinical efficacy [45]. The gene discussed is FASLG; the disease is glioblastoma.